You are here

Dendreon

Dendreon ups its Provenge marketing game with help from NBA all-star Grant Hill

Dendreon ups its Provenge marketing game with help from NBA all-star Grant Hill

Fierce Pharma

pharma marketing

prostate cancer

celebrity endorsements

Flag link:

Dendreon makes leap to become cell therapy CMO

Dendreon makes leap to become cell therapy CMO

Biopharma Reporter

Flag link:

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy

Endpoints

Alpine Immune Sciences

Flag link:

Dendreon commits to prostate cancer vaccine Provenge with new lease for manufacturing site

Dendreon commits to prostate cancer vaccine Provenge with new lease for manufacturing site

Fierce Pharma

prostate cancer

drug manufacturing

Flag link:

ASCO: Dendreon touts T-cell response data for prostate cancer vaccine Provenge

ASCO: Dendreon touts T-cell response data for prostate cancer vaccine Provenge

Fierce Pharma

prostate cancer

Flag link:

Dendreon eyes real-world data boost for lagging prostate cancer med Provenge

Dendreon eyes real-world data boost for lagging prostate cancer med Provenge

Fierce Pharma

prostate cancer

Flag link:

Former Dendreon CEO debuts new public company in reverse merger

Former Dendreon CEO debuts new public company in reverse merger

BioPharma Dive

Alpine Immune Sciences

Flag link:

Valeant: Why The Dendreon Sale Changes Everything

Valeant: Why The Dendreon Sale Changes Everything

Seeking Alpha

Valeant Pharmaceuticals

Flag link:

JPM: Valeant sells off Dendreon, skincare brands for $2.1B

JPM: Valeant sells off Dendreon, skincare brands for $2.1B

BioPharma Dive

Valeant Pharmaceuticals

Chinese Sanpower Group

Flag link:

In Juno patient deaths, echoes seen of earlier failed company

In Juno patient deaths, echoes seen of earlier failed company

Stat

Juno Therapeutics

clinical trials

Flag link:

Former Dendreon CEO Secures $48M for Cancer Immunotherapy Startup

Former Dendreon CEO Secures $48M for Cancer Immunotherapy Startup

Forbes

cancer immunotherapy

Alpine Immune Sciences

Flag link:

Valeant welcomes Dendreon into the fold with a 77-job shearing

Valeant welcomes Dendreon into the fold with a 77-job shearing

Fierce Pharma

Valeant Pharmaceuticals

Flag link:

Can Valeant transform Dendreon's ailing Provenge into a viable cancer competitor?

Can Valeant transform Dendreon's ailing Provenge into a viable cancer competitor?

Fierce Pharma Marketing

Valeant Pharmaceuticals

prostate cancer

Flag link:

Valeant Pharmaceuticals Signs Stalking-Horse Deal With Dendreon Corporation (DNDN)

Valeant Pharmaceuticals Signs Stalking-Horse Deal With Dendreon Corporation (DNDN)

Bidness Etc.

Valeant Pharmaceuticals

Flag link:

Biotech investor explains why Juno Therapeutics won't be like Dendreon

Biotech investor explains why Juno Therapeutics won't be like Dendreon

Bizjournals.com

Juno Therapeutics

Flag link:

Dendreon heads to February bankruptcy auction without initial bidder

Dendreon heads to February bankruptcy auction without initial bidder

Bizjournals.com

Flag link:

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

TheStreet.com

Vertex Pharmaceuticals

Myriad Genetics

Flag link:

Dendreon's Alternate Reality

Dendreon's Alternate Reality

Motley Fool

prostate cancer

Flag link:

Don’t expect a Dendreon sale; the troubled biotech will likely end up as a new entity with the current common shares cancelled

Don’t expect a Dendreon sale; the troubled biotech will likely end up as a new entity with the current common shares cancelled

Barron's

Flag link:

Are Expensive Biotech Drugs Bad For Business?

Are Expensive Biotech Drugs Bad For Business?

Seeking Alpha

Bristol-Myers Squibb

Gilead Sciences

Teva Pharmaceutical

Vertex Pharmaceuticals

Flag link:

Pages